p16INK4a and p14ARF methylation as a potential biomarker for human bladder cancer
Authors:
- Hideki EnokidaHEHideki Enokida
- Takenari GotandaTGTakenari Gotanda
- Hiroyuki KuboHKHiroyuki Kubo
- Kenryu NishiyamaKNKenryu Nishiyama
- Motoshi KawaharaMKMotoshi Kawahara
- Masayuki NakagawaMNMasayuki Nakagawa
- 1 January 2006
- journal article
- clinical trial
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 339 (3) , 790-796
Abstract
No abstract availableKeywords
This publication has 29 references indexed in Scilit:
- CpG Hypermethylation of MDR1 Gene Contributes to the Pathogenesis and Progression of Human Prostate CancerCancer Research, 2004
- Genetic Alterations of p16INK4a and p14ARF Genes in Human Bladder CancerJournal of Urology, 2003
- CpG hypermethylation of promoter region and inactivation of E‐cadherin gene in human bladder cancerMolecular Carcinogenesis, 2002
- Aberrations of the p14ARF and p16INK4a Genes in Renal Cell CarcinomasJapanese Journal of Cancer Research, 2001
- Deletions of the INK4A Gene in Superficial Bladder TumorsThe American Journal of Pathology, 1999
- Clinical Significance of mdm2 and p53 Expression in Bladder CancerOncology, 1999
- The INK4a/ARF tumor suppressor: one gene—two products—two pathwaysTrends in Biochemical Sciences, 1998
- The Relationship Among Multiple Recurrences, Progression and Prognosis of Patients with Stages TA and T1 Transitional Cell Cancer of the Bladder Followed for at least 20 yearsJournal of Urology, 1995
- A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4Nature, 1993
- Metachronous multifocal development of urothelial cancers by intraluminal seedingThe Lancet, 1993